Lucitanib: Additional Phase II data

Additional data from the Phase IIa extension of an open-label, dose-escalation Phase I trial showed that once-daily 10, 15 or 20 mg lucitanib led to 6 objective responses and 6 cases of stable disease in breast cancer patients with amplification of either FGFR1 or an FGF ligand-containing amplicon (n=12). Median progression-free survival (PFS) was 9.6 months, median duration of response was 11.5 months and median time to first response was 1.8 months. In patients who were potentially sensitive to anti-angiogenic agents (n=27), lucitanib led to 3 complete responses, 4 partial responses and 15 cases of stable disease. Median PFS was 5.9 months and median duration of response was 7.5 months. There were 3 grade 4 adverse events, 1 each of increased lipase levels, increased blood uric acid and depressed level of consciousness. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...